(Q28171273)

https://api.crossref.org/works/10.1517/13543784.13.11.1469

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.11.1469

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.11.1469

Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.11.1469

Memantine in moderate-to-severe Alzheimer's disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Inflammation, autotoxicity and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Nonsteroidal anti-inflammatory drugs and Alzheimer disease: what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Double placebo design in a prevention trial for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

The effects of a novel NSAID on chronic neuroinflammation are age dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß 42 by Inhibiting Rho

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469

Amyloid beta and Alzheimer disease therapeutics: the devil may be in the details

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1469